Maxstan

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Maxstan

Quick Facts

Property Description
Active ingredient Mefenamic Acid
Form Oral solid forms (capsules, tablets)
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common use Relief from pain, inflammation, and fever
Origin Synthetic compound

What Type of Medicine is Maxstan (Mefenamic Acid)?

Maxstan is the commercial name for a pharmaceutical agent defined by the core component Mefenamic Acid, which serves as its International Nonproprietary Name (INN). The drug is chemically defined as a synthetic organic compound and is classified within the fenamate subgroup of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). This classification means the drug's primary function is to serve as an analgesic, an anti-inflammatory, and an antipyretic agent. Mefenamic Acid is clinically recognized for its effectiveness in managing acute painful conditions where inflammation is present, such as soft tissue discomfort. The Mefenamic Acid component works by inhibiting the production of prostaglandins, which are chemical mediators of pain, fever, and the body’s inflammatory response.


Composition, Forms, and General Therapeutic Purpose

The overall composition of Maxstan includes Mefenamic Acid as the sole therapeutic agent, combined with necessary inactive excipients used to create stable oral solid forms, such as tablets and capsules. This formulation is intended for systemic action through oral administration. The general therapeutic purpose of Maxstan is to provide comprehensive relief from symptoms associated with both acute pain and inflammation. Mefenamic Acid is recognized for its utility as a standard non-opioid analgesic. This reflects the drug's established role in mitigating pain and reducing elevated body temperature, which is achieved by targeting the source of the symptoms through its antiprostaglandin activity.

What side effects are possible with Maxstan?

Possible Side Effects and Safety Information: Maxstan

Maxstan, like other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), is associated with a range of officially documented adverse reactions, including serious warnings issued by regulatory authorities (e.g., FDA/EMA). Factual statements about Maxstan's safety are based strictly on governmental regulatory documents.


Serious and Clinically Significant Risks

Regulatory documents emphasize two critical, potentially fatal risks:

  • Cardiovascular Thrombotic Events: Maxstan may increase the risk of serious cardiovascular thrombotic events, including myocardial infarction (MI) and stroke. This risk can occur early in treatment and may increase with duration of use and at higher doses. It is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
  • Gastrointestinal (GI) Events: The drug can cause serious GI adverse events, including inflammation, bleeding, ulceration, and perforation of the stomach or intestines, which may be fatal. These events can occur at any time, often without warning symptoms.

Other serious adverse reactions include hepatotoxicity (liver damage), renal toxicity (kidney damage) with potential for hyperkalemia, anaphylactic reactions (severe allergic reactions), and serious skin reactions (e.g., Stevens-Johnson Syndrome, DRESS).


Population-Specific Safety Considerations and Restrictions

Category Safety Consideration/Restriction
Pregnancy Contraindicated in the third trimester due to the risk of fetal toxicity (e.g., premature closure of the fetal ductus arteriosus). Use around 20 weeks' gestation or later should be highly restricted.
Pre-existing Conditions Contraindicated in patients with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs, significantly impaired renal function, or active/severe liver disease.
Dose/Exposure The lowest effective dose should be used for the shortest duration possible to minimize potential risk for adverse cardiovascular events.

Patients should be monitored for signs of hepatic injury, hypertension, fluid retention, and hematological toxicity during therapy.

Overdose and Emergency Response

Maxstan Overdose and when to seek help

The official regulatory profile for Maxstan (Mefenamic Acid) defines specific clinical manifestations and mandated actions required following an overdose.

Property Description
Documented Overdose Presentations Symptoms include Gastrointestinal (epigastric pain, nausea, vomiting, GI bleeding) and Central Nervous System (drowsiness, lethargy, confusion, tremor).
Physiological Systems Affected CNS, GI, and Renal system (risk of Acute Renal Failure).
Emergency-Response Statements Seek immediate medical attention for any suspected overdose. Management is generally non-antidotal.
When Immediate Medical Help Is Required Urgent help is required upon the occurrence of severe manifestations, including convulsions, profound CNS depression, or hypotension.

Overdose Management and Monitoring

Classification Description
Severity Classification Overdose may lead to life-threatening outcomes such as Acute Renal Failure, Metabolic Acidosis, or Coma.
Overdose-Context Constraints Management requires monitoring of vital signs and renal function. No specific antidote is known.

Official Overdose Statements

  • Severe outcomes explicitly documented include Acute Renal Failure, Metabolic Acidosis, and Convulsions.
  • The primary approach is symptomatic and supportive treatment, with potential consideration for activated charcoal or gastric lavage.
  • Increased risk of severe outcomes is noted in patients with pre-existing renal impairment and elderly patients.

The official regulatory framework explicitly mandates the necessity of immediate medical intervention for a suspected overdose, establishing that the condition may progress from documented GI and CNS symptoms to severe systemic effects. Management relies on supportive measures and rigorous hospital monitoring of vital functions and kidney health, as no specific antidote is available to reverse the effects.

Therapeutic Uses of Maxstan

What Maxstan Treats: Main Uses and Benefits

Maxstan (Mefenamic Acid) is commonly used across domains where additional symptomatic support is needed, addressing symptoms related to physical discomfort and symptoms related to inflammatory or irritative states during periods of acute discomfort. It is used to help with pain and Primary Dysmenorrhea (menstrual cramps). The drug is applied in addressing symptom clusters that may appear suddenly or fluctuate, contributing to easing the overall symptom load.

Relief for Acute Discomfort

The medication is relevant in conditions characterized by episodic or fluctuating manifestations, generally providing support for mild to moderate pain and symptoms associated with inflammation. It is applied in scenarios where additional management of discomfort is required, such as easing headaches, dental pain, or managing temporary pain following procedures or childbirth. Maxstan is also applied in addressing symptoms that become more disruptive during symptom intensification associated with conditions like Osteoarthritis and Rheumatoid Arthritis.

The primary benefit is relevant for easing symptoms that interfere with daily comfort, and may assist with maintaining functional stability when symptoms become more noticeable.

Quick Fact: Supportive Symptom Management
Primary Focus Mild to moderate pain and inflammatory symptoms
Key Scenarios Menstrual cramps, temporary post-procedure discomfort, symptom intensification
Practical Benefit Contributes to improved comfort during symptomatic periods

Regulatory References

  1. NIH DailyMed overview

Eligibility and Restrictions for Use

Official Population Eligibility for Maxstan (Mefenamic Acid)

Regulatory documents define specific populations who are eligible, restricted, or prohibited from using Maxstan. The medicine is typically approved for use in adults and adolescents 14 years of age and older who do not have contraindications.

Contraindicated Populations (Must Not Use)

Maxstan is formally contraindicated and must not be used by individuals with the following conditions, based on official regulatory labeling:

  • Known hypersensitivity to Mefenamic Acid or a history of allergic reactions (asthma, urticaria) to Aspirin or other NSAIDs.
  • Active gastrointestinal ulceration or chronic inflammation of the GI tract.
  • Severe renal, hepatic, or cardiac failure.
  • Treatment of pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
  • Patients in the last trimester of pregnancy (after 30 weeks).

Restricted and Age-Related Eligibility

  • Age: Use is generally not established for pediatric patients under 14 years of age. Elderly patients require caution due to an increased risk of severe gastrointestinal and renal events.
  • Physiological State: The medicine is not recommended for nursing mothers or for women attempting to conceive (potential to impair fertility).
  • Conditional Use: Patients with uncontrolled hypertension or a history of GI bleeding should only use Maxstan under careful consideration by a healthcare professional.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Maxstan (Mefenamic Acid) interaction patterns are documented in regulatory prescribing information, defining several mandatory constraints for co-administration. All statements are grounded in official government drug labels.

Prohibited and High-Risk Combinations

Co-administration is prohibited with other systemic non-aspirin Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) due to a significantly increased risk of serious gastrointestinal events. Mefenamic Acid is also contraindicated for treating pain following Coronary Artery Bypass Graft (CABG) surgery because of documented cardiovascular thrombotic risks.

Documented Pharmacokinetic and Pharmacodynamic Effects

Mefenamic Acid can enhance the effect of oral anticoagulants, including Warfarin, by displacing them from protein binding sites, which increases the risk of bleeding. This bleeding risk is also heightened when Maxstan is combined with SSRIs.

Maxstan reduces the renal clearance of Lithium, leading to elevated plasma levels and potential toxicity. Furthermore, it can reduce the antihypertensive efficacy of agents like ACE-inhibitors and Diuretics, which increases the risk of renal function deterioration.

The ingestion of magnesium-containing antacids is documented to significantly increase the overall systemic exposure of Mefenamic Acid. Alcohol (Ethanol) consumption concurrently increases the risk of stomach bleeding.

Population-Specific Notes

Official documentation notes that elderly patients and those with impaired renal function are at greater risk for serious adverse outcomes when using certain combination drugs, such as Diuretics or ACE-inhibitors, due to heightened risk of renal complications.

Mechanism of Action

Maxstan (Mefenamic Acid) engages fundamental biological mechanisms by acting as a modulator of inflammatory and nociceptive signaling pathways. Its action is centered on inhibiting key enzymes and the consequent decrease in chemical mediators.

Enzyme Inhibition and Mediator Suppression

The drug functions by exerting reversible, competitive inhibition against the Cyclooxygenase (COX) enzymes (both COX-1 and COX-2). This mechanism halts the production of PGE2 and other prostaglandins, which are responsible for activating and amplifying physiological responses.

Modulation of Pain and Fever Signaling

The reduced availability of prostaglandins decreases the sensitization of peripheral nociceptors (pain-sensing nerves) and modifies signaling in the hypothalamic thermoregulatory center. This process limits the downstream consequence of excessive signaling and facilitates the re-regulation of an elevated thermal set point.

Attenuation of Vascular Inflammation

By reducing prostaglandin production, the drug reduces the chemical signals that trigger vasodilation and increased vascular permeability. This action limits the downstream effects of the inflammatory cascade on blood vessel function, which results in a modified physiological state within the tissue.

Dosage and Administration Information

How to use Maxstan: Official Administration Guidelines

Maxstan must be administered only by intravenous (IV) infusion under the supervision of a healthcare professional in a clinical setting equipped to manage potential infusion-related reactions. Administration is restricted to patients 18 years of age and older.


Dosing and Preparation

Stage Dose Infusion Time Frequency
Initial Dose 50 mg/kg 30 minutes Single dose
Maintenance Dose 25 mg/kg 30 minutes Every 4 weeks (monthly)

Preparation Steps:

  1. Reconstitution: Reconstitute the lyophilized powder with 5 mL of Sterile Water for Injection, which yields a concentration of 10 mg/mL. The vial must be gently swirled; do not shake.
  2. Dilution: Immediately transfer the entire reconstituted solution into a sterile IV bag containing 100 mL of 0.9% Sodium Chloride Injection for final dilution before administration.

Administration Procedures

The infusion must be delivered using a controlled infusion pump to ensure the total dose is administered slowly over a period of at least 30 minutes. The administration timing is independent of meals.

Missed Dose Instructions: If a maintenance dose is missed, administer it as soon as possible. The schedule for all subsequent maintenance doses must then be adjusted to occur every four weeks following the newly administered dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Maxstan


Evidence for use in Primary Dysmenorrhea (Menstrual Pain)

Research exploring how symptoms change over time in Primary Dysmenorrhea has primarily relied on Randomized Controlled Trials (RCTs), with findings consolidated in Systematic Reviews and Meta-analyses. The studies were used in research exploring outcomes related to physical discomfort. Researchers focused on monitoring metrics like reported pain intensity and the use of additional pain relief medicines during the menstrual cycle.

Findings describe patterns observed in the studies related to changes in overall symptom duration and severity compared to control groups. Multiple trials monitored whether individuals in the study group differed in the amount of additional pain relief required over the measured period than those in the placebo groups. However, the existing evidence is limited to acute, single-cycle follow-up. This means that long-term effects are not fully established.


Evidence for use in Acute Mild to Moderate Pain

Maxstan was evaluated in research contexts involving fluctuating or unstable symptoms of acute pain. The evidence base includes numerous Randomized Controlled Trials (RCTs) comparing Maxstan to both a placebo (dummy pill) and other widely available pain relievers. The main research examined outcomes such as the degree of pain relief observed over defined time intervals and how participants assessed their Patient Global Assessment of Pain Relief.

Studies explored patterns related to symptom intensity or variability over short periods. Data for certain groups remain insufficient, as the follow-up durations were limited, generally not exceeding a week. The evidence base is characterized by a heterogeneity of pain models (e.g., pain from a dental procedure is different from muscle strain). This means that the findings reflect the specific conditions under which they were conducted, and researchers continue to explore how these findings translate across every specific acute pain scenario.


Research Gaps and Remaining Uncertainties

Long-term effects are not fully established, as follow-up durations were limited in the primary studies. For use in chronic conditions like arthritis, the limited follow-up periods (typically three months or less) provide no evidence regarding any influence on the underlying progression of the disease or structural joint changes. The research also describes patterns related to short-term changes but does not provide individual predictions, particularly because the evidence is heterogeneous.

Key Studies & References

  1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) - StatPearls (NIH/NCBI Bookshelf)
  2. Mefenamic Acid - LiverTox: Clinical and Research Information on Drug-Induced Liver Injury (NIH/NCBI Bookshelf)

Frequently Asked Questions (FAQ)

Common questions about Maxstan (FAQ)


Q: How quickly does Maxstan typically start working?

According to official regulatory documents, the active ingredient in Maxstan is rapidly absorbed after being taken orally. The drug is reported to reach its mean peak plasma levels (highest concentration in the bloodstream) approximately two to four hours following administration of a single dose.


Q: What is the average time before Maxstan reaches its full effect?

Peak plasma concentrations are generally attained in two to four hours. When multiple doses are administered, stable concentrations in the body, consistent with the drug’s short half-life, are typically reached by the second day of treatment. This information is based on the pharmacological properties defined in official prescribing information.


Q: Is Maxstan intended for short-term or long-term use?

Official labeling defines the use of Maxstan strictly for short-term treatment only, typically not exceeding seven days, to manage acute pain or primary dysmenorrhea. Regulatory warnings emphasize that the lowest effective dose should be used for the shortest possible duration to minimize potential risk.


Q: What are the most commonly reported side effects of Maxstan?

Official regulatory safety data indicates that Maxstan is associated with common side effects, primarily involving the digestive system. These most often include issues like diarrhea, general stomach discomfort, nausea, or vomiting.


Q: What are the signs of a serious or less common side effect from Maxstan?

Signs of serious adverse events that have been reported include: chest pain, weakness on one side of the body, slurred speech, black/tarry stools, vomiting material that looks like coffee grounds, swelling of the face or limbs, or yellowing of the skin or eyes (jaundice). This information is based on regulatory warnings.


Q: Are there different strengths or formulations of Maxstan available?

The active component, Mefenamic Acid, is generally available in oral solid forms, such as capsules and tablets. Standard strengths documented in regulatory drug listings commonly include 500 mg formulations.


Q: Can Maxstan cause changes in mood or sleep patterns?

The official product information notes that the active ingredient may cause effects on the central nervous system (CNS). Documented side effects include feelings of drowsiness, fatigue, or dizziness. In rare cases or in contexts such as overdose, more severe CNS symptoms like disorientation or changes in mental status have been reported.


Q: What is the risk of dependence or withdrawal symptoms associated with Maxstan?

Maxstan is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) and is a non-opioid analgesic. Based on this classification, the active ingredient is generally not associated with the risk of dependence or withdrawal symptoms typically seen with controlled substances.


Q: Does Maxstan interact with common foods or specific diets?

Official documents state that the effect of common food on the absorption of the active ingredient has not been thoroughly studied. However, the concomitant ingestion of antacids containing magnesium hydroxide is documented to significantly increase the rate of the drug's absorption.


Q: Can Maxstan affect laboratory test results?

Official labeling suggests that the active ingredient may have an effect on certain lab tests. It has been associated with changes in parameters that monitor kidney and liver function and may impact tests that measure blood clotting time, such as prothrombin time (PT).


Q: What is considered an overdose of Maxstan and what are the signs?

Symptoms reported in cases of overdose may include extreme tiredness, nausea, vomiting, stomach pain, acute kidney injury (AKI), and central nervous system effects such as seizures or coma. Official safety information describes these potential serious outcomes.


Q: How long after stopping Maxstan will it stay in my system?

The active ingredient has a relatively short elimination half-life of approximately two hours. However, its breakdown products (metabolites) may have longer half-lives and can accumulate in individuals with impaired kidney or liver function.


Q: Is it normal to feel [mild, non-serious symptom] when first starting Maxstan?

Official patient information notes that mild, non-serious symptoms such as stomach discomfort, diarrhea, or heartburn are listed among the more common side effects that can occur when beginning treatment. These occurrences are consistent with general NSAID use.


Q: Why do official documents mention Maxstan's effect on [a specific organ/system]?

Regulatory documents describe effects on specific organ systems (e.g., gastrointestinal, cardiovascular, renal) because the drug’s mechanism of action affects processes in these areas. The regulatory mandate requires outlining all associated serious risks in detail to ensure public safety.


Q: Is Maxstan used for any condition other than its main approved use?

Official indications in regulatory labeling strictly define the use of Maxstan only for the treatment of primary dysmenorrhea and mild to moderate acute pain for a limited duration. Use is restricted to these approved conditions.


Q: Are there any common reasons patients stop taking Maxstan?

Official documents note that discontinuation of Maxstan is often driven by the occurrence of adverse effects. Specifically, the regulatory label notes that symptoms like diarrhea or signs of gastrointestinal irritation are documented reasons for patients to stop the medication.


Q: Is it safe to take over-the-counter pain relievers while using Maxstan?

Official regulatory warnings advise against combining Maxstan with other systemic non-aspirin NSAIDs due to a high risk of serious gastrointestinal events. The concomitant use of Maxstan with aspirin is also not consistently recommended because it may increase the risk of bleeding complications.


Q: Can Maxstan affect a person's ability to drive or operate machinery?

Official documents carry a caution stating that patients should not drive or operate machinery if they experience side effects such as drowsiness, dizziness, fatigue, or visual disturbance. These effects may impair judgment and motor skills.


Q: Does Maxstan have any black box warnings mentioned in the official labeling?

Yes, the official regulatory labeling in the US includes a prominent Boxed Warning to highlight critical safety information. This warning emphasizes the increased risk of serious cardiovascular events (e.g., heart attack, stroke) and serious gastrointestinal events (e.g., life-threatening bleeding and perforation).


Q: Does Maxstan interact with herbal products like St. John's Wort?

While Maxstan's specific label may not list every herbal product, regulatory information notes the potential for certain herbs, like St. John's Wort, to interact with medications processed by liver enzymes. Information regarding the simultaneous use of this medication with herbal products requires consultation.


Q: Is it okay to crush or split Maxstan tablets?

The official labeling does not provide specific instructions for altering the physical form of the tablets or capsules. Generally, oral solid forms should be swallowed whole unless the medicine is scored or a specific liquid formulation is provided for that purpose.

How should Maxstan be stored and disposed of?

Maxstan (Mefenamic Acid) must be stored and handled according to specific conditions defined in official regulatory labeling to ensure product integrity.

Official Storage Requirements

Item Requirement
Temperature Controlled Room Temperature (15 C to 30 C).
Protection Protect from moisture and excessive heat.
Container Store in the original container, kept tightly closed.
Child Safety Keep out of the sight and reach of children.

Official Disposal Rules

To dispose of unused or expired Maxstan, use an official drug take-back program or pharmacy collection point. If these options are not available, the medication can be discarded in household trash. This requires mixing the medicine with an undesirable substance, such as coffee grounds or dirt, and placing the mixture in a sealed container before disposal. The medicine must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Maxstan found in:

A-Z Index: